A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Ariz. man auctioning comic book collection to pay for cancer treatmenton August 17, 2019 at 2:29 pm
PHOENIX (KNXV/CNN) – Robert Letscher spent most of his life collecting comic books. Now he’s selling off his prized possessions to cover growing medical costs. An Arizona man is auctioning his prized ...
- Comics Relief: “X-Men” collection auctioned to fund cancer treatmenton August 17, 2019 at 5:06 am
(KPNX) — Ever since he can remember, Robert Letscher has been enthralled with comic books. The 55-year-old turned his passion into an online career. “It’s how I paid for this house,” Letscher said ...
- Simple dietary changes may reduce cancer risk, increase lifespanon August 17, 2019 at 1:58 am
It may help beat stress, boost thinking, decrease cancer risk, and reduce arthritis. However, too much can cause heart arrhythmias. Find out more. Read now A large new study warns that many people ...
- UPDATE 2-Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvion August 16, 2019 at 7:02 pm
Aug 16 (Reuters) - Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly ...
- Mt. Juliet woman works extra shifts to pay for husband's cancer treatmenton August 16, 2019 at 4:06 pm
With medical bills piling up, a Mt. Juliet woman must work extra shifts to help cover her husband's cancer treatments ...
- Thyroid cancer worry remains after treatmenton August 16, 2019 at 10:07 am
More than half of a cohort of adults with thyroid cancer identified disease recurrence, quality-of-life deterioration and familial risk as areas of concern following diagnosis, according to findings ...
- Roche prices personalized cancer treatment at about $204,560 annuallyon August 16, 2019 at 7:56 am
(Reuters) - Roche Holding AG priced at about $204,560 a year its personalized cancer treatment, Rozlytrek, which targets tumors with specific genetic mutations, the Swiss drugmaker said. The treatment ...
- Oregon mom accused of defying court order for daughter cancer treatment, turns self inon August 15, 2019 at 5:13 pm
An Oregon woman has turned herself in after being accused of defying a court order to deliver her daughter to state custody to receive surgery to remove a cancerous tumor on her liver. The woman ...
- FDA Approves Another Tumor-Agnostic Cancer Drugon August 15, 2019 at 2:53 pm
Additionally, the drug was similarly approved for the treatment of metastatic, ROS1-positive non-small cell lung cancer (NSCLC). For the first approval, the drug is to be used in patients with locally ...
via Bing News